Skip to main content

Table 1 Patient, tumor, treatment characteristics, outcomes

From: A pilot study of stereotactic body radiation therapy (SBRT) after surgery for stage III non-small cell lung cancer

Patient No.

Clinical TNM

Pathologic TNM

TEMLA Positive Stations (# positive/total)

PTV

Recurrence

Alive

1

T3 N2 M0

N2

4R(3/13)

53.35

N

N

2

T3 N2 M0

T3 N2

4R(11/14) 10R(1/4)

170.21

Y (SCV LN s/p RT, currently NED)

Y

3

T2aN2 M0

ypT2bN2

4 L(1/11)

47

Y (Brain s/p RT, currently NED)

Y

4

T1N3M0

ypT1bN3

4R(7/7) 5(1/1) 6(3/3) 7(1/1)

166

Y (liver)

N

5

T1aN3M0

T1aN3

4R(2/3)

52.2

N

Y

6

T2N3M0

T4 N3

4R(4/4) 4 L(1/1) 7(1/1) 10R(2/2) 11R(1/1)

154.75

Y (SCV LN s/p RT)

N

7

T2N3M0

ypT2aN2

5(2/2) 10 L(3/5)

89.19

Y (Brain s/p RT, currently NED)

Y

8

T1bN2 M0

ypT2aN2

7(2/9)

56.16

Y (pleural effusion)

N

9

T1aN2 M0

ypT1aN2

4 L(1/1) 11 L(3/8)

33.14

N

Y

10

T2aN2 M0

ypT1bN2

2R(2/2) 4R(5/6) 7(2/3) 9R(1/1) 10R(2/4) 11R(1/1)

94.2

Y (liver and brain; ALK-mutant)

Y

  1. Patient 1 received SBRT to the primary tumor
  2. All received 10 Gy to the positive nodal areas
  3. All patients except 1,2 had adenocarcinoma
  4. All patients except 2, 5, 6 received neoadjuvant chemotherapy
  5. All patients except 3 received adjuvant chemotherapy
  6. M male, F female, PTV = Planning Target Volume in cubic centimeters, SCV supraclavicular, s/p status post, RT radiation therapy, NED no evidence of disease
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us